II/III期胃癌微卫星不稳定与PD-L1表达:CLASSIC随机对照试验事后分析
该研究对CLASSIC试验中592例II/III期胃癌患者进行事后分析,检测MSI状态及PD-L1表达。MSI-H占6.8%,肿瘤细胞PD-L1阳性占2.7%,间质免疫细胞PD-L1阳性占28.4%。MSI-H和间质PD-L1阳性是独立预后因素;辅助化疗仅使MSS组DFS获益,MSI-H组无获益;MSS组中间质PD-L1阴性者化疗获益显著。
要点
- MSI-H是II/III期胃癌独立良好预后因素,辅助化疗未见DFS获益。
- 间质免疫细胞PD-L1阳性率28.4%,为独立预后因素。
- MSS且间质PD-L1阴性患者从辅助化疗中显著获益。
核心结论
- MSI状态和PD-L1表达是可操作的生物标志物,用于II/III期胃癌D2术后分层和预测辅助化疗获益。
研究设计与样本
- CLASSIC随机对照试验的事后分析,收集入组患者的肿瘤标本和临床信息,评估MSI状态和PD-L1表达。
主要发现
- 592例患者中40例(6.8%)为MSI-H。
- 582例可评估免疫组化患者中,肿瘤细胞PD-L1阳性16例(2.7%),间质免疫细胞PD-L1阳性165例(28.4%)。
- 多变量分析显示MSI-H和间质PD-L1阳性是DFS独立预后因素,风险比分别为0.301(0.123-0.736)和0.714(0.514-0.991),P=0.008和0.044。
- 辅助化疗改善MSS组DFS(5年DFS 66.8% vs 54.1%,P=0.002),MSI-H组无获益(5年DFS 83.9% vs 85.7%,P=0.931)。
- MSS组中间质PD-L1阴性患者接受辅助化疗较单纯手术有显著生存获益(5年DFS 66.1% vs 50.7%,P=0.001),间质PD-L1阳性患者无显著获益。
临床怎么用
- 对II/III期胃癌D2术后患者检测MSI状态和PD-L1表达,以分层预测辅助化疗获益。
- MSI-H患者可能不推荐辅助化疗,MSS且间质PD-L1阴性患者可从辅助化疗中显著获益。
局限性
- 为CLASSIC试验的事后分析,样本量有限,MSI-H和肿瘤细胞PD-L1阳性亚组例数较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigated microsatellite instability (MSI) status and programed cell death ligand 1 (PD-L1) expression as predictors of prognosis and responsiveness to chemotherapy for stage II/III gastric cancer. BACKGROUND: The clinical implications of MSI status and PD-L1 expression in gastric cancer have not been well-elucidated. METHODS: Tumor specimens and clinical information were collected from patients enrolled in the CLASSIC trial-a randomized controlled study of capecitabine plus oxaliplatin-based adjuvant chemotherapy. Five quasi-monomorphic mononucleotide markers were used to assess tumor MSI status. PD-L1 expressions of tumor and stromal immune cells were evaluated using immunohistochemistry. RESULTS: Of 592 patients, 40 (6.8%) had MSI-high (MSI-H) tumors. Among 582 patients available for immunohistochemistry evaluation, PD-L1 was positive in tumor cells (tPD-L1) of 16 patients (2.7%) and stromal immune cells (sPD-L1) of 165 patients (28.4%). Multivariable analysis of disease-free survival (DFS) showed that MSI-H and sPD-L1-positivity were independent prognostic factors [hazard ratio 0.301 (0.123-0.736), 0.714 (0.514-0.991); P = 0.008, 0.044), as were receiving chemotherapy, age, tumor grade, and TNM stage. Although adjuvant chemotherapy improved DFS in the microsatellite-stable (MSS) group (5-year DFS: 66.8% vs 54.1%; P = 0.002); no benefit was observed in the MSI-H group (5-year DFS: 83.9% vs 85.7%; P = 0.931). In the MSS group, sPD-L1-negative patients, but not sPD-L1-positive patients, had significant survival benefit from adjuvant chemotherapy compared with surgery only (5-year DFS: 66.1% vs 50.7%; P = 0.001). CONCLUSION: MSI status and PD-L1 expression are clinically actionable biomarkers for stratifying patients and predicting benefit from adjuvant chemotherapy after D2 gastrectomy for stage II/III gastric cancer.
引用
- Choi YY, Kim H, Shin SJ, et al. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg. 2019. PMID: 29727332. doi:10.1097/SLA.0000000000002803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。